|
Gene: PLCL2 |
Gene summary for PLCL2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | PLCL2 | Gene ID | 23228 |
Gene name | phospholipase C like 2 | |
Gene Alias | PLCE2 | |
Cytomap | 3p24.3 | |
Gene Type | protein-coding | GO ID | GO:0001659 | UniProtAcc | Q9UPR0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23228 | PLCL2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.48e-04 | -4.09e-01 | 0.0155 |
23228 | PLCL2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.66e-04 | 2.62e-01 | -0.1954 |
23228 | PLCL2 | HTA11_866_3004761011 | Human | Colorectum | AD | 4.23e-04 | -4.29e-01 | 0.096 |
23228 | PLCL2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.30e-09 | -3.99e-01 | 0.0674 |
23228 | PLCL2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.64e-20 | -5.07e-01 | 0.294 |
23228 | PLCL2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 1.81e-15 | -4.88e-01 | 0.3859 |
23228 | PLCL2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 9.12e-03 | -5.01e-01 | 0.2585 |
23228 | PLCL2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.38e-17 | -5.04e-01 | 0.3005 |
23228 | PLCL2 | A015-C-203 | Human | Colorectum | FAP | 2.48e-12 | -3.35e-01 | -0.1294 |
23228 | PLCL2 | A015-C-204 | Human | Colorectum | FAP | 1.00e-03 | -3.62e-01 | -0.0228 |
23228 | PLCL2 | A002-C-201 | Human | Colorectum | FAP | 1.15e-02 | -2.32e-01 | 0.0324 |
23228 | PLCL2 | A001-C-119 | Human | Colorectum | FAP | 1.68e-03 | -3.77e-01 | -0.1557 |
23228 | PLCL2 | A001-C-108 | Human | Colorectum | FAP | 1.46e-06 | -3.27e-01 | -0.0272 |
23228 | PLCL2 | A002-C-205 | Human | Colorectum | FAP | 9.70e-10 | -3.64e-01 | -0.1236 |
23228 | PLCL2 | A015-C-006 | Human | Colorectum | FAP | 3.92e-04 | -2.78e-01 | -0.0994 |
23228 | PLCL2 | A015-C-106 | Human | Colorectum | FAP | 1.08e-03 | -2.60e-01 | -0.0511 |
23228 | PLCL2 | A002-C-114 | Human | Colorectum | FAP | 9.44e-09 | -4.14e-01 | -0.1561 |
23228 | PLCL2 | A015-C-104 | Human | Colorectum | FAP | 1.45e-11 | -1.73e-01 | -0.1899 |
23228 | PLCL2 | A001-C-014 | Human | Colorectum | FAP | 5.65e-04 | -2.28e-01 | 0.0135 |
23228 | PLCL2 | A002-C-016 | Human | Colorectum | FAP | 5.01e-09 | -3.08e-01 | 0.0521 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0051098 | Colorectum | AD | regulation of binding | 126/3918 | 363/18723 | 6.01e-10 | 4.88e-08 | 126 |
GO:0051099 | Colorectum | AD | positive regulation of binding | 66/3918 | 173/18723 | 1.47e-07 | 6.64e-06 | 66 |
GO:0043393 | Colorectum | AD | regulation of protein binding | 68/3918 | 196/18723 | 5.17e-06 | 1.34e-04 | 68 |
GO:0032092 | Colorectum | AD | positive regulation of protein binding | 33/3918 | 85/18723 | 1.22e-04 | 1.78e-03 | 33 |
GO:0018105 | Colorectum | AD | peptidyl-serine phosphorylation | 88/3918 | 315/18723 | 1.73e-03 | 1.43e-02 | 88 |
GO:0018209 | Colorectum | AD | peptidyl-serine modification | 92/3918 | 338/18723 | 3.19e-03 | 2.36e-02 | 92 |
GO:0048017 | Colorectum | AD | inositol lipid-mediated signaling | 53/3918 | 182/18723 | 5.35e-03 | 3.52e-02 | 53 |
GO:0048015 | Colorectum | AD | phosphatidylinositol-mediated signaling | 52/3918 | 178/18723 | 5.37e-03 | 3.54e-02 | 52 |
GO:0106106 | Colorectum | AD | cold-induced thermogenesis | 43/3918 | 144/18723 | 7.05e-03 | 4.31e-02 | 43 |
GO:0120161 | Colorectum | AD | regulation of cold-induced thermogenesis | 43/3918 | 144/18723 | 7.05e-03 | 4.31e-02 | 43 |
GO:1990845 | Colorectum | AD | adaptive thermogenesis | 46/3918 | 157/18723 | 7.97e-03 | 4.73e-02 | 46 |
GO:00510982 | Colorectum | MSS | regulation of binding | 113/3467 | 363/18723 | 3.55e-09 | 2.41e-07 | 113 |
GO:00510992 | Colorectum | MSS | positive regulation of binding | 59/3467 | 173/18723 | 7.11e-07 | 2.53e-05 | 59 |
GO:00433932 | Colorectum | MSS | regulation of protein binding | 62/3467 | 196/18723 | 6.44e-06 | 1.69e-04 | 62 |
GO:00320921 | Colorectum | MSS | positive regulation of protein binding | 29/3467 | 85/18723 | 4.44e-04 | 5.32e-03 | 29 |
GO:00181052 | Colorectum | MSS | peptidyl-serine phosphorylation | 81/3467 | 315/18723 | 8.92e-04 | 9.12e-03 | 81 |
GO:00182091 | Colorectum | MSS | peptidyl-serine modification | 84/3467 | 338/18723 | 2.12e-03 | 1.79e-02 | 84 |
GO:00510984 | Colorectum | FAP | regulation of binding | 81/2622 | 363/18723 | 1.04e-05 | 2.97e-04 | 81 |
GO:00181053 | Colorectum | FAP | peptidyl-serine phosphorylation | 71/2622 | 315/18723 | 2.51e-05 | 5.82e-04 | 71 |
GO:00510994 | Colorectum | FAP | positive regulation of binding | 44/2622 | 173/18723 | 4.52e-05 | 9.40e-04 | 44 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLCL2 | SNV | Missense_Mutation | c.1529N>A | p.Ala510Asp | p.A510D | Q9UPR0 | protein_coding | deleterious(0.05) | probably_damaging(0.98) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
PLCL2 | SNV | Missense_Mutation | novel | c.2008C>A | p.Arg670Ser | p.R670S | Q9UPR0 | protein_coding | deleterious(0.02) | possibly_damaging(0.657) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCL2 | SNV | Missense_Mutation | novel | c.2695G>A | p.Gly899Arg | p.G899R | Q9UPR0 | protein_coding | deleterious(0.03) | possibly_damaging(0.568) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCL2 | SNV | Missense_Mutation | rs369130951 | c.706N>A | p.Ala236Thr | p.A236T | Q9UPR0 | protein_coding | deleterious(0.03) | probably_damaging(0.932) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLCL2 | SNV | Missense_Mutation | c.2700N>T | p.Lys900Asn | p.K900N | Q9UPR0 | protein_coding | deleterious(0) | possibly_damaging(0.821) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLCL2 | SNV | Missense_Mutation | rs760913644 | c.2648G>A | p.Arg883Gln | p.R883Q | Q9UPR0 | protein_coding | tolerated(0.08) | benign(0.332) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
PLCL2 | SNV | Missense_Mutation | novel | c.709G>T | p.Asp237Tyr | p.D237Y | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLCL2 | SNV | Missense_Mutation | novel | c.763N>T | p.His255Tyr | p.H255Y | Q9UPR0 | protein_coding | tolerated(0.22) | possibly_damaging(0.806) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PLCL2 | SNV | Missense_Mutation | novel | c.1376N>G | p.Tyr459Cys | p.Y459C | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
PLCL2 | SNV | Missense_Mutation | novel | c.2134N>A | p.Asp712Asn | p.D712N | Q9UPR0 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |